TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03238625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and sodium bicarbonate
Description: Lidocaine and sodium bicarbonate ratio 3:1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and sodium bicarbonate
Description: Lidocaine and sodium bicarbonate ratio 9:1
Study: NCT04664504

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemoradiotherapy Radiotherapy
Description: 50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Radiotherapy
Description: 25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local dose increase of Short-course Radiotherapy
Description: 25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: Total mesorectal excision
Study: NCT03238625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injection
Study: NCT04664504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision
Study: NCT02190799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
Study: NCT03411876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® pendant nasal cannula
Description: Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® pendant nasal cannula
Description: Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional nasal cannula
Description: Supplemental oxygen is provided by a conventional nasal cannula.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional nasal cannula
Description: Supplemental oxygen is provided by a conventional nasal cannula.
Study: NCT03995212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 1.0 mg
Description: Oral CR845 1.0 mg administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo administered twice daily
Study: NCT03947151

Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix injection(s)
Description: 1 or 2 degarelix injection(s)
Study: NCT03238625

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium cloride 0.9%
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium cloride 0.9%
Description: Placebo
Study: NCT00863265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00235144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-coated Bx Velocity stent
Description: drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated Bx Velocity stent
Description: bare-metal stent
Study: NCT01511068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukine
Description: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
Study: NCT01821859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
Study: NCT04215900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-speed yoga multi-directional yoga
Description: The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
Study: NCT00555672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT03079089

Intervention type: DRUG
Group type: OTHER
Intervention: Sequential Packaging (SET)
Description: Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)

Intervention type: DRUG
Group type: OTHER
Intervention: Transfusion graft
Description: Graft of peripheral stem cells is preferred at DO

Intervention type: DRUG
Group type: OTHER
Intervention: Prevention of GVHD
Description: * Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)

Intervention type: DRUG
Group type: OTHER
Intervention: Care supports
Description: According to the protocols of each center

Intervention type: DRUG
Group type: OTHER
Intervention: Lymphocyte injection of prophylactic donor (PDLI)
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II.
Study: NCT02540954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: A dose of 2 mg aflibercept injected intravitreally
Study: NCT01145339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactase
Description: 1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactase
Description: 1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
Study: NCT01359943

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).
Study: NCT01539473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA with Tyramine
Description: TR-701 FA 200 mg oral and Tyramine
Study: NCT02540954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: A dose of 2 mg aflibercept injected intravitreally
Study: NCT01359943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..
Study: NCT03925727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavilermide ophthalmic solution
Description: BID topical dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavilermide ophthalmic solution
Description: BID topical dosing
Study: NCT03623568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir tablets
Description: 12 weeks of treatment with Mavyret
Study: NCT03722524

Intervention type: DRUG
Intervention: amlodipine / indapamide / perindopril arginine FDC
Description: CCB / diuretic / ACE inhibitor
Study: NCT03925727

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID topical dosing
Study: NCT01103570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystocholangiography
Description: a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystic duct cholangiography
Description: Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
Study: NCT03935243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: equine assisted therapy
Description: The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: activating control phase
Description: The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
Study: NCT02176161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended Release 750mg
Description: Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended Release 750mg
Description: Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended Release 750mg
Description: Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
Study: NCT02443168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Part 1: oral solution containing 100 mg \[14C\]-AG-221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Part 1: oral solution containing 100 mg \[14C\]-AG-221

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 14C AG-221
Description: 5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
Study: NCT00766714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook K-SOFT-5100 catheter
Description: A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frydman classical catheter
Description: A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
Study: NCT03933228

Intervention type: PROCEDURE
Intervention: Interscalene-Cervical Plexus Block
Description: Ultrasound-Guided Combined Interscalene-Cervical Plexus Block

Intervention type: PROCEDURE
Intervention: Supraclavicular-Cervical Plexus Block
Description: Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
Study: NCT02932748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Portion Controlled Meals (PCM)
Description: Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Portion Controlled Meals (PCM)
Description: Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone (GP)
Description: Weight management program delivered via group conference call.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet
Description: Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Phone (IP)
Description: Weight management program delivered via individual phone call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Weight management topics delivered face-to-face at clinic office every 6 months.
Study: NCT00913939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Guided Needles to deliver HDR Brachytherapy
Description: Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Guided Needles to deliver HDR Brachytherapy
Description: Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
Study: NCT00596830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871 (Figitumumab)
Description: CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
Study: NCT02056093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV mode
Description: Application of PSV in all patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV mode
Description: Application of PAV mode in all patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Study: NCT03326206

Intervention type: OTHER
Intervention: COPE Program
Description: The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
Study: NCT04298957

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cone biopsy
Description: Cone biopsy if transformation Zone (TZ) 2 or TZ 3
Study: NCT01539473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-controlled withTyramine
Description: Placebo-controlled and Tyramine
Study: NCT01527292

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiation Therapy
Description: SRT only

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT with Vertebral Augmentation Procedure
Description: SRT with VAP
Study: NCT03011359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimizing B.I (New) PCA mode
Description: In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional PCA mode
Description: (Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
Study: NCT03913091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Bupivacaine HCL
Description: 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
Study: NCT00903812

Intervention type: OTHER
Intervention: No intervention
Description: No intervention as observational study
Study: NCT02231346

Intervention type: DRUG
Intervention: Berodual® Respimat® - inhaler
Study: NCT04289116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: We Test
Description: This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IHTC
Description: Individual HIV Testing and Counseling
Study: NCT02273219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
Study: NCT03359811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetic Solution
Description: A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.